Skip to main content

ProShares Ultra Nasdaq Biotechnology (BIB)

NASDAQ: BIB · IEX Real-Time Price · USD
104.79 -2.20 (-2.06%)
Sep 24, 2021 10:44 AM EDT - Market open
Assets$291.12M
NAV$103.97
Expense Ratio0.95%
PE Ration/a
Shares Out2.80M
Dividend (ttm)n/a
Dividend Yieldn/a
Ex-Dividend DateSep 21, 2010
1-Year Return
-
Volume9,162
Open106.00
Previous Close106.99
Day's Range104.03 - 105.34
52-Week Low62.45
52-Week High113.06
Beta1.95
Holdings276
Inception DateApr 8, 2010

About BIB

The investment seeks daily investment results that correspond to two times (2x) the daily performance of the Nasdaq Biotechnology Index. The fund invests in financial instruments that ProShare Advisors believes, in combination, should produce daily returns consistent with the fund's investment objective. The index is a modified capitalization weighted index that includes securities of Nasdaq listed companies that are classified as either biotechnology or pharmaceutical. The fund is non-diversified.

Asset ClassEquity
SectorBiotech
RegionNorth America
IssuerProShares
Stock ExchangeNASDAQ
Ticker SymbolBIB
Index TrackedNASDAQ Biotechnology Index

Top 10 Holdings

71.73% of assets
NameSymbolWeight
NASDAQ Biotechnology Index SWAP UBS AG N/A14.96%
NASDAQ Biotechnology Index SWAP Citibank NA N/A11.11%
NASDAQ Biotechnology Index SWAP Goldman Sachs International N/A11.05%
NASDAQ Biotechnology Index SWAP Societe Generale N/A10.85%
Net Other Assets / Cash N/A8.09%
NASDAQ Biotechnology Index SWAP Bank of America NA N/A4.33%
ModernaMRNA3.58%
AmgenAMGN2.90%
Gilead SciencesGILD2.76%
IlluminaILMN2.10%
View More Holdings

Dividends

Ex-DividendAmountPay Date
Sep 22, 2021$0.00Sep 29, 2021
Jun 22, 2021$0.00Jun 29, 2021
Mar 23, 2021$0.00Mar 30, 2021
Mar 23, 2016$1.0E-6Apr 1, 2016
Full Dividend History

News

Could Biotech ETFs Get Another Boost From JNJ News?

This has been a pivotal week for biotech news, as Johnson & Johnson said Wednesday that a booster shot of its COVID-19 vaccine generated a promising immune response in early stage clinical trials. This ...

Other symbols:IBBJPBE
4 weeks ago - ETF Trends

Tap the Red Hot Biotech Sector With These 2 Leveraged ETFs

Investors could easily tap the bullish trend by considering a near-term long on the biotech sector.

Other symbols:JNJLABUMRNAPFETRIL
4 weeks ago - Zacks Investment Research

Pfizer-BioNTech COVID-19 Vaccine Garners Full FDA Approval

The FDA has officially given full approval to Pfizer and BioNTech for their COVID-19 vaccine, potentially making way for more approvals and more vaccine mandates, reports CNBC. It is a move that officia...

Other symbols:BNTXPFE
1 month ago - ETF Trends

Biotech ETFs Are Already Benefitting from Pfizer Vaccine's Full Approval

There could be big gains ahead for biotech ETFs, as the Food and Drug Administration on Monday fully approved the Pfizer and BioNTech coronavirus vaccine, making it the first vaccine in the U.S. to be a...

Other symbols:IBBJPBE
1 month ago - ETF Trends

As Covid Cases Mutate, the Biotech Industry Works to Keep Up

As the Delta variant sweeps across the globe, pharmaceutical and biotech companies are working to ensure vaccines continue to cover the population, as well as working on booster doses that can adapt to ...

2 months ago - ETF Trends

5 Best Leveraged ETFs of Last Week

We highlight a few leveraged ETF areas that won last week.

3 months ago - Zacks Investment Research

Top-Performing Biotechnology ETFs Amid Coronavirus Outbreak

From vaccine-related progress to development of cell therapies for the treatment of coronavirus, all kept the rally in the biotech sector alive.

Other symbols:ARKGIDNAXBI
1 year ago - Zacks Investment Research

4 Best-Performing Leveraged ETF Areas of Last Week

Last week witnessed a tug-of-war between bulls and bears.

1 year ago - Zacks Investment Research